NCT07162181 2026-04-17Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersEli Lilly and CompanyPhase 2 Active not recruiting13 enrolled
NCT07516093 2026-04-08Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNurix Therapeutics, Inc.Phase 3 Not yet recruiting620 enrolled